Update: Vitamin D3 and calcium carbonate supplementation for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology (VITALITY trial): study protocol for a randomised placebo-controlled trial
Authors: Dzavakwa Nyasha Veronica , Chisenga Molly , McHugh Grace , Filteau Suzanne , Gregson Celia Louise , Kasonka Lackson , Kranzer Katharina , Mabuda Hildah Banda , Mujuru Hilda , Redzo Nicol , Rowland-Jones Sarah , Schaible Ulrich E. , Simms Victoria , Ferrand Rashida Abbas ,   the VITALITY team, Hameiri-Bowen Dan , Gea-Mallorqui Esther , Hauptmann Matthias , Kahari Cynthia , Leschczyk Christoph , Madanhire Tafadzwa , Manyanga Tadious , Mutasa Kudakwashe , Rukobo Sandra , Rukuni Ruramayi , Mudzingwa Tsitsi S. , Sunkutu Veronica , Tembo Mizinga , Namukonda Cassandra , Kelly Paul , Martineau Adrian , Ward Kate , Archary Moherndran , Pettifor John , John-Stewart Grace , Kekitiinwa Adeodata , Lombard Carl , Weiss Helen A. 
Published: July 2024

Background

Of the 2 million children living with HIV globally, 90% live in sub-Saharan Africa. Despite antiretroviral therapy, longstanding HIV infection is associated with several chronic complications in children including growth failure, particularly stunting and delayed puberty. Vitamin D deficiency, which is highly prevalent among children living with HIV in sub-Saharan Africa, has further adverse impact on bone health. This trial aims to establish whether supplementation with vitamin D3 and calcium carbonate improves musculoskeletal health among peripubertal children living with HIV. This paper is an update to an already existing protocol that was previously published in Trials in 2022 and details changes in the trial outcomes.

Methods/design

We will conduct an individually randomised, double-blinded, placebo-controlled trial of weekly high-dose vitamin D3 (20,000 IU) plus daily calcium carbonate (500 mg) supplementation for 48 weeks. Eight hundred and forty children living with HIV aged 11–19 years taking ART for ≥ 6 months will be enrolled and followed up for 96 weeks. The primary outcome is DXA-measured total body less-head bone mineral density Z-score (TBLH-BMD) at 48 weeks and is an update to the previous primary outcome total body less-head bone mineral content adjusted for lean mass (TBLH-BMCLBM) Z-score. The primary outcome was updated to address the substantial differences in distributions of TBLH-BMCLBM Z-score between the two sites as a result of software differences of the DXA machines. Secondary outcomes are DXA-measured TBLH-BMD Z-score adjusted for height at 48 weeks a new secondary outcome, lumbar spine bone mineral apparent density Z-score, number of respiratory infections, lean muscle mass and grip-strength at 48 and 96 weeks, and TBLH-BMD Z-score at 96 weeks. Sub-studies will investigate the effect of the intervention on vitamin D3 pathway metabolites and markers of bone turnover, intestinal microbiota, and innate and acquired immune function.

Discussion

This is the largest trial to date of vitamin D supplementation in children living with HIV. Intervening to address deficits in bone accrual through childhood is critical for optimising adolescent and early adult bone health, and prevention of later adult osteoporotic fractures. Trial results will draw attention to the need to screen for and treat long-term comorbidities in children living with HIV in resource-limited settings.

Trial registration

Pan African Clinical Trials Registry PACTR20200989766029. Registered on September 3, 2020. URL of trial registry record: https://pactr.samrc.ac.za

Trial status

Participant follow-up completed; data analysis ongoing.